According to the Zhitong Finance App, Zoli Pharmaceutical (300181.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1,764 billion yuan, an increase of 10.30% over the previous year. Achieved net profit of 375 million yuan attributable to shareholders of listed companies, an increase of 0.38% over the previous year. Achieved net profit of 374 million yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 0.53% over the previous year.

The revenue of the Wuling series decreased by 0.82% compared to the same period of the previous year, the revenue of the Bering series increased by 12.87% compared to the same period of the previous year, the revenue of traditional Chinese medicine tablets decreased by 13.82% compared to the same period of the previous year, the revenue of traditional Chinese medicine formula granules increased by 31.29% compared to the same period of the previous year, and the sales revenue of the Duowei series increased by 49.97% compared to the same period of the previous year.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.